Zakład Chemii Biomolekularnej
Zakład Chemii Biomolekularnej
Zakład Chemii Biomolekularnej

Publikacje

Prace oryginalne:

2018

1. Długosz A, Drogosz J, Deredas D, Janecki T, Janecka A. Involvement of a coumarin analog AD-013 in the DNA damage response pathways in MCF-7 cells. Mol Biol Rep. 2018; doi: 10.1007/s11033-018-4271-z.

2. Koszuk J, Bartosik T, Wojciechowski J, Wolf WM, Janecka A, Drogosz J, Długosz A, Krajewska U, Mirowski M, Janecki T. Synthesis of 3-Methylidene-1-tosyl-2,3-dihydroquinolin-4(1H)-ones as Potent Cytotoxic Agents. Chem Biodivers. 2018; e1800242. doi: 10.1002/cbdv.201800242.

3. Długosz A, Gach-Janczak K, Szymański J, Deredas D, Janecki T, Janecka A. Involvement of α-methylene-γ- and δ-lactones in the suppression of multidrug resistance in MCF-7 cells. Pharmacol Rep. 2018; 70(4): 631-638.

4. Gach-Janczak K, Piekielna-Ciesielska J, Adamska-Bartłomiejczyk A, Wtorek K, Ferrari F, Calo' G, Szymaszkiewicz A, Piasecka-Zelga J, Janecka A. In vitro and in vivo activity of cyclopeptide Dmt-c[d-Lys-Phe-Asp]NH2, a mu opioid receptor agonist biased toward β-arrestin. Peptides. 2018; 105: 51-57.

5. Piekielna-Ciesielska J, Ferrari F, Calo' G, Janecka A. Cyclopeptide Dmt-[D-Lys-p-CF3-Phe-Phe-Asp]NH2; a novel G protein-biased agonist of the mu opioid receptor. Peptides. 2018; 101: 227-233.

6. Długosz A, Gach-Janczak K, Szymański J, Deredas D, Krawczyk H, Janecki T, Janecka A. Anticancer properties of a new hybrid analog AD-013 combining a coumarin scaffold with an α-methylene-δ-lactone motif. Anticancer Agents Med Chem. 2018; 18(3): 450-457.

2017

1. Adamska-Bartłomiejczyk A, Borics A, Tömböly C, Dvorácskó S, Lisowski M, Kluczyk A, Wołczański G, Piekielna-Ciesielska J, Janecka A. Synthesis, receptor binding studies, optical spectroscopic and in silico structural characterization of morphiceptin analogs with cis-4-amino-L-proline residues. J Pept Sci. 2017; 23(12): 864-870.

2. Gach-Janczak K, Piekielna-Ciesielska J, Adamska-Bartłomiejczyk A, Perlikowska R, Kruszyński R, Kluczyk A, Krzywik J, Sukiennik J, Cerlesi MC, Calo G, Wasilewski A, Zielińska M, Janecka A. Synthesis and activity of opioid peptidomimetics with β2- and β3-amino acids. Peptides. 2017; 95: 116-123.

3. Zubrzycki M, Janecka A, Liebold A, Ziegler M, Zubrzycka M. Effects of centrally administered endocannabinoids and opioids on orofacial pain perception in rats. Br J Pharmacol. 2017; 174(21): 3780-3789.

4. Pacuła AJ, Kaczor KB, Antosiewicz J, Janecka A, Długosz A, Janecki T, Wojtczak A, Ścianowski J. New Chiral Ebselen Analogues with Antioxidant and Cytotoxic Potential. Molecules. 2017; 22(3). pii: E492.

5. Adamska-Bartłomiejczyk A, Janecka A, Szabó MR, Cerlesi MC, Calo G, Kluczyk A, Tömböly C, Borics A. Cyclic mu-opioid receptor ligands containing multiple N-methylated amino acid residues. Bioorg Med Chem Lett. 2017; 27(8): 1644-1648.

6. Adamska-Bartłomiejczyk A, De Marco R, Gentilucci L, Kluczyk A, Janecka A. Design and characterization of opioid ligands based on cycle-in-macrocycle scaffold. Bioorg Med Chem. 2017; 25(8): 2399-2405.

7. Jakubowski R, Pomorska DK, Długosz A, Janecka A, Krajewska U, Różalski M, Mirowski M, Bartosik T, Janecki T. Synthesis of 4,4-Disubstituted 3-Methylidenechroman-2-ones as Potent Anticancer Agents. ChemMedChem. 2017; 12(8): 599-605.

8. Pacuła AJ, Kaczor KB, Wojtowicz A, Antosiewicz J, Janecka A, Długosz A, Janecki T, Ścianowski J. New glutathione peroxidase mimetics-Insights into antioxidant and cytotoxic activity. Bioorg Med Chem. 2017; 25(1): 126-131.

9. Długosz A, Gach K, Szymański J, Modranka J, Janecki T, Janecka A. Anticancer activity of new molecular hybrids combining 1,4-naphthalenedione motif with phosphonic acid moiety in hepatocellular carcinoma HepG2 cells. Acta Biochim Pol. 2017; 64(1): 41-48.

2016

1. Gach K, Modranka J, Szymański J, Pomorska D, Krajewska U, Mirowski M, Janecki T, Janecka A. Anticancer properties of new synthetic hybrid molecules combining naphtho[2,3-b]furan-4,9-dione or benzo[f]indole-4,9-dione motif with phosphonate subunit. Eur J Med Chem. 2016; 120: 51-63.

2. Piekielna J, De Marco R, Gentilucci L, Cerlesi MC, Calo' G, Tömböly C, Artali R, Janecka A. Redoubling the ring size of an endomorphin-2 analog transforms a centrally acting mu-opioid receptor agonist into a pure peripheral analgesic. Biopolymers. 2016; 106(3): 309-17.

3. Adamska A, Kluczyk A, Cerlesi MC, Calo G, Janecka A, Borics A. Synthesis, biological evaluation and structural analysis of novel peripherally active morphiceptin analogs. Bioorg Med Chem. 2016; 24(7): 1582-8.

4. Gach K, Grądzka I, Wasyk I, Męczyńska-Wielgosz S, Iwaneńko T, Szymański J, Koszuk J, Janecki T, Kruszewski M, Janecka A. Anticancer activity and radiosensitization effect of methyleneisoxazolidin-5-ones in hepatocellular carcinoma HepG2 cells. Chem Biol Interact. 2016; 248: 68-73.

5. Perlikowska R, Piekielna J, Gentilucci L, De Marco R, Cerlesi MC, Calo G, Artali R, Tömböly C, Kluczyk A, Janecka A. Synthesis of mixed MOR/KOR efficacy cyclic opioid peptide analogs with antinociceptive activity after systemic administration. Eur J Med Chem. 2016; 109: 276-86.

2015

1. Adamska A, Kolesińska B, Kluczyk A, Kamiński ZJ, Janecka A. Synthesis of linear and cyclic opioid-based peptide analogs containing multiple N-methylated amino acid residues. J Pept Sci. 2015 Sep 24. doi: 10.1002/psc.2804.

2. Piekielna J, Perlikowska R, do-Rego JC, do-Rego JL, Cerlesi MC, Calo G, Kluczyk A, Łapiński K, Tömböly C, Janecka A. Synthesis of mixed opioid affinity cyclic endomorphin-2 analogs with fluorinated phenylalanines. ACS Med Chem Lett. 2015; 6: 579-83.

3. Piekielna J, Kluczyk A, Gentilucci L, Cerlesi MC, Calo' G, Tomböly C, Łapiński K, Janecki T, Janecka A. Ring size in cyclic endomorphin-2 analogs modulates receptor binding affinity and selectivity. Org Biomol Chem. 2015; 13: 6039-46.

4. Gach K, Szymański J, Pomorska D, Długosz A, Modranka J, Michalak M, Janecki T, Janecka A. Anticancer properties of novel 4-methylene-1,2-diphenylpyrazolidin-3-ones. Chem Biol Drug Des. 2015 Apr 1. doi: 10.1111/cbdd.12565.

5. Gach K, Szymański J, Pomorska D, Długosz A, Modranka J, Janecki T, Janecka A. Combined effects of anticancer drugs and new synthetic α-methylene-δ-lactones on MCF-7 cells. Tumour Biol. 2015; 36: 5971-7.

6. Gach K, Belkacemi O, Lefranc B, Perlikowski P, Masson J, Walet-Balieu ML, Do-Rego JC, Galas L, Schapman D, Lamtahri R, Tonon MC, Vaudry D, Chuquet J, Leprince J. Detection, characterization and biological activities of [bisphospho-thr3,9]ODN, an endogenous molecular form of ODN released by astrocytes. Neuroscience. 2015; 290: 472-84.

7. Modranka J, Jakubowski R, Różalski M, Krajewska U, Janecka A, Gach K, Pomorska D, Janecki T. Design, synthesis and cytotoxic evaluation of 4-methylidenepyrazolidin-3-ones. Eur J Med Chem. 2015; 92: 565-74.

2014

1. Piekielna J, Gentilucci L, De Marco R, Perlikowska R, Adamska A, Olczak J, Mazur M, Artali R, Modranka J, Janecki T, Tömböly C, Janecka A. Cyclic side-chain-linked opioid analogs utilizing cis- and trans-4-aminocyclohexyl-d-alanine. Bioorg Med Chem. 2014; 23: 6545-6551.

2. Perlikowska R, Piekielna J, Mazur M, Koralewski R, Olczak J, do Rego JC, Fichna J, Modranka J, Janecki T, Janecka A. Antinociceptive and antidepressant-like action of endomorphin-2 analogs with proline surrogates in position 2. Bioorg Med Chem. 2014; 22: 4803-4809.

3. Perlikowska R, Malfacini D, Cerlesi MC, Calo' G, Piekielna J, Floriot L, Henry T, do-Rego JC, Tömböly C, Kluczyk A, Janecka A. Pharmacological characterization of endomorphin-2-based cyclic pentapeptides with methylated phenylalanine residues. Peptides 2014; 55: 145-150.

4. Wyrebska A, Pawlowska Z, Gach K, Komorowski P, Protas A, Walkowiak B, Janecka A. Proteomic analysis of proteins engaged in α-methylene-δ-lactone cytotoxic effects in hormone-independent breast cancer MDA-MB-231 cells. Chem Biol Drug Des. 2014; 84: 300-306.

5. Piekielna J, Kluczyk A, Perlikowska R, Janecka A. Cyclic pentapeptide analogs based on endomorphin-2 structure: cyclization studies using liquid chromatography combined with on-line mass spectrometry and tandem mass spectrometry. Peptides 2014; 55: 32-40.

6. Perlikowska R, Piekielna J, Fichna J, do-Rego JC, Toth G, Janecki T, Janecka A. Pharmacological properties of novel cyclic pentapeptides with µ-opioid receptor agonist activity. Med Chem. 2014; 10: 154-161.

Prace przeglądowe

1. Perlikowska R, Janecka A. Rubiscolins - highly potent peptides derived from plant proteins. Mini Rev Med Chem. 2017 Apr 26. doi: 10.2174/1389557517666170426160703.

2. Dlugosz A, Janecka A. Novobiocin Analogs as Potential Anticancer Agents. Mini Rev Med Chem. 2017; 17(9): 728-733.

3. Dlugosz A, Janecka A. ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy. Curr Pharm Des. 2016; 22(30): 4705-4716.

4. Pomorska DK, do-Rego JC, do-Rego JL, Zubrzycka M, Janecka A. Opioid and Cannabinoid System in Food Intake. Curr Pharm Des. 2016; 22(10): 1361-70.

5. Zubrzycki M, Janecka A, Zubrzycka M. Trigemino-hypoglossal somatic reflex in the pharmacological studies of nociception in orofacial area. Acta Neurobiol Exp (Wars). 2015; 75(3): 253-63.

6. Zubrzycka A, Zubrzycki M, Janecka A, Zubrzycka M. New horizons in the etiopathogenesis and Non-Invasive diagnosis of endometriosis. Curr Mol Med. 2015 Sep 20.

7. De Marco R, Janecka A. Strategies to improve bioavailability and in vivo efficacy of the endogenous opioid peptides endomorphin-1 and endomorphin-2. Curr Top Med Chem. 2015; 16: 141-55.

8. Gach K, Długosz A, Janecka A. The role of oxidative stress in anticancer activity of sesquiterpene lactones. Naunyn Schmiedebergs Arch Pharmacol. 2015; 388: 477-86.

9. Pomorska DK, Gach K, Janecka A. Immunomodulatory effects of endogenous and synthetic peptides activating opioid receptors. Mini Rev Med Chem. 2014; 14: 1148-55.

10. Janecka A, Gentilucci L. Cyclic endomorphin analogs in targeting opioid receptors to achieve pain relief. Future Med Chem. 2014; 6: 2093-2101.

11. Gach K, Janecka A. α-Methylene-γ-lactones as a novel class of anti-leukemic agents. Anticancer Agents Med Chem. 2014; 14: 688-694.

12. Wyrebska A, Gach K, Janecka A. Combined effect of parthenolide and various anti-cancer drugs or anti-cancer candidate substances on malignant cells in vitro and in vivo. Mini Rev Med Chem. 2014; 14: 222-228.

13. Perlikowska R, Janecka A. Bioavailability of endomorphins and the blood-brain barrier-a review. Med Chem. 2014; 10: 2-17.

14. Zubrzycki M, Liebold A, Janecka A, Zubrzycka M. A new face of endocannabinoids in pharmacotherapy. Part II: role of endocannabinoids in inflammation-derived cardiovaascular diseases. J Physiol Pharmacol. 2014; 65: 183-191.

15. Zubrzycki M, Liebold A, Janecka A, Zubrzycka M. A new face of endocannabinoids in pharmacotherapy. Part I: protective role of endocannabinoids in hypertension and myocardial infarction. J Physiol Pharmacol. 2014; 65:171-181.

 

Zakład Chemii Biomolekularnej